Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy

The tumor microenvironment (TME) fosters cancer progression by supporting the differentiation and proliferation of myeloid‐derived suppressor cells (MDSCs), which play a critical role in suppressing immune responses and facilitating tumor growth. Recent findings by Dahal et al. reveal that platelet‐...

Full description

Saved in:
Bibliographic Details
Main Authors: Qi Yan, Hemn Mohammadpour
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Molecular Oncology
Subjects:
Online Access:https://doi.org/10.1002/1878-0261.13758
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841556045142425600
author Qi Yan
Hemn Mohammadpour
author_facet Qi Yan
Hemn Mohammadpour
author_sort Qi Yan
collection DOAJ
description The tumor microenvironment (TME) fosters cancer progression by supporting the differentiation and proliferation of myeloid‐derived suppressor cells (MDSCs), which play a critical role in suppressing immune responses and facilitating tumor growth. Recent findings by Dahal et al. reveal that platelet‐activating factor (PAF), a lipid mediator elevated in the TME, contributes to the differentiation of neutrophils into immunosuppressive neutrophils. They showed that inhibiting PAF signaling reduces MDSC‐mediated immunosuppression, thereby enhancing cytotoxic T‐cell activity. This approach may improve cancer immunotherapy outcomes, particularly when combined with checkpoint blockade therapies, suggesting a promising avenue for therapeutic development.
format Article
id doaj-art-8e09ad54428d4e01b35ea2d754f1090c
institution Kabale University
issn 1574-7891
1878-0261
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Molecular Oncology
spelling doaj-art-8e09ad54428d4e01b35ea2d754f1090c2025-01-07T14:42:32ZengWileyMolecular Oncology1574-78911878-02612025-01-01191111410.1002/1878-0261.13758Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapyQi Yan0Hemn Mohammadpour1Department of Cell Stress Biology Roswell Park Comprehensive Cancer Center Buffalo NY USADepartment of Cell Stress Biology Roswell Park Comprehensive Cancer Center Buffalo NY USAThe tumor microenvironment (TME) fosters cancer progression by supporting the differentiation and proliferation of myeloid‐derived suppressor cells (MDSCs), which play a critical role in suppressing immune responses and facilitating tumor growth. Recent findings by Dahal et al. reveal that platelet‐activating factor (PAF), a lipid mediator elevated in the TME, contributes to the differentiation of neutrophils into immunosuppressive neutrophils. They showed that inhibiting PAF signaling reduces MDSC‐mediated immunosuppression, thereby enhancing cytotoxic T‐cell activity. This approach may improve cancer immunotherapy outcomes, particularly when combined with checkpoint blockade therapies, suggesting a promising avenue for therapeutic development.https://doi.org/10.1002/1878-0261.13758immune therapyMDSCneutrophilPAFtumor microenvironment
spellingShingle Qi Yan
Hemn Mohammadpour
Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy
Molecular Oncology
immune therapy
MDSC
neutrophil
PAF
tumor microenvironment
title Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy
title_full Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy
title_fullStr Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy
title_full_unstemmed Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy
title_short Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy
title_sort platelet activating factor a potential therapeutic target to improve cancer immunotherapy
topic immune therapy
MDSC
neutrophil
PAF
tumor microenvironment
url https://doi.org/10.1002/1878-0261.13758
work_keys_str_mv AT qiyan plateletactivatingfactorapotentialtherapeutictargettoimprovecancerimmunotherapy
AT hemnmohammadpour plateletactivatingfactorapotentialtherapeutictargettoimprovecancerimmunotherapy